[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

November 2021 | 38 pages | ID: I96E94B7AAEEN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which focuses on the development of vaccines in the area of immune-oncology. The company develops immunotherapies that activates immune system of cancer patients to identify and eradicate tumors. The company’s pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for treatment of mixed advanced solid tumours (MAST) and metastic triple negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales, Australia.

Imugene Ltd Key Recent Developments

Jun 10,2021: Imugene appoints Dr Monil Shah as Chief Business Officer
Apr 23,2021: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2021
Dec 10,2020: Imugene receives $4.82 million R&D tax incentive
Sep 30,2020: Imugene appoints Dr Rita Laeufle as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Imugene Ltd - Key Facts
Imugene Ltd - Key Employees
Imugene Ltd - Key Employee Biographies
Imugene Ltd - Major Products and Services
Imugene Ltd - History
Imugene Ltd - Company Statement
Imugene Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Imugene Ltd - Business Description
Imugene Ltd - SWOT Analysis
SWOT Analysis - Overview
Imugene Ltd - Strengths
Imugene Ltd - Weaknesses
Imugene Ltd - Opportunities
Imugene Ltd - Threats
Imugene Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Imugene Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 10, 2021: Imugene appoints Dr Monil Shah as Chief Business Officer
Apr 23, 2021: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2021
Dec 10, 2020: Imugene receives $4.82 million R&D tax incentive
Sep 30, 2020: Imugene appoints Dr Rita Laeufle as Chief Medical Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Imugene Ltd, Key Facts
Imugene Ltd, Key Employees
Imugene Ltd, Key Employee Biographies
Imugene Ltd, Major Products and Services
Imugene Ltd, History
Imugene Ltd, Subsidiaries
Imugene Ltd, Key Competitors
Imugene Ltd, Ratios based on current share price
Imugene Ltd, Annual Ratios
Imugene Ltd, Annual Ratios (Cont...1)
Imugene Ltd, Interim Ratios
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Imugene Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Imugene Ltd, Performance Chart (2017 - 2021)
Imugene Ltd, Ratio Charts
Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


More Publications